Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Siddharth M PatelYu Mi KangKyungAh ImBrendon L NeuenStefan D AnkerDeepak L BhattJaved ButlerDavid Z I CherneyBrian Lee ClaggettRobert A FletcherWilliam G HerringtonCatherine M ViscoliMeg J JardineKenneth W MahaffeyDarren K McGuireJohn Joseph Valentine McMurrayBruce C NealMilton PackerVlado PerkovicScott D SolomonNatalie StaplinMuthiah VaduganathanChristoph WannerDavid Collins WheelerFaiez ZannadYujie ZhaoHiddo J Lambers HeerspinkMarc S SabatineStephen D WiviottPublished in: Circulation (2024)
SGLT2i reduce the risk of MACE across a broad range of patients irrespective of atherosclerotic cardiovascular disease, diabetes, kidney function, or other major clinical characteristics at baseline. This effect is driven primarily by a reduction of cardiovascular death, particularly HF death and sudden cardiac death, without a significant effect on myocardial infarction in the overall population, and no effect on stroke. These data may help inform selection for SGLT2i therapies across the spectrum of cardiovascular-kidney-metabolic disease.
Keyphrases
- cardiovascular disease
- systematic review
- type diabetes
- heart failure
- end stage renal disease
- ejection fraction
- atrial fibrillation
- newly diagnosed
- randomized controlled trial
- emergency department
- electronic health record
- quality improvement
- adipose tissue
- skeletal muscle
- metabolic syndrome
- big data
- weight loss
- data analysis
- drug induced
- adverse drug
- brain injury
- case control